



GOOD PEOPLE
for GOOD HEALTH

February 4, 2025

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code : 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Outcome of meeting of Board of Directors

In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular nos. CIR/CFD/CMD/4/2015 dated September 09, 2015 and SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, enclosed please find:

1. Unaudited standalone financial results for the quarter and nine months ended on December 31, 2024 accompanied by limited review report.
2. Unaudited consolidated financial results for the quarter and nine months ended on December 31, 2024 accompanied by limited review report.

These financial results have been approved and taken on record by the Board of Directors at its meeting held today, which commenced at 3.30 p.m. and concluded at 6.32 p.m.

We request you to take the above on record.

Thanking you,

Yours faithfully,

For J.B. Chemicals & Pharmaceuticals Ltd

Sandeep Phadnis
Vice President – Secretarial
& Company Secretary

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Energy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500
secretarial@jbpharma.com



GOOD PEOPLE
for GOOD HEALTH

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024

(₹ in lakhs)

| Particulars | Quarter ended | | | Nine months ended | | Year ended |
|--|---------------|------------|------------|-------------------|------------|------------|
| | 31/12/2024 | 30/09/2024 | 31/12/2023 | 31/12/2024 | 31/12/2023 | 31/03/2024 |
| | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| 1. Revenue from operations | 91,351 | 95,576 | 80,010 | 2,82,158 | 2,48,944 | 3,29,864 |
| 2. Other income | 716 | 889 | 661 | 2,121 | 1,858 | 3,468 |
| 3. Total income (1+2) | 92,067 | 96,465 | 80,671 | 2,84,279 | 2,50,802 | 3,33,332 |
| 4. Expenses | | | | | | |
| a) Cost of materials consumed | 20,018 | 17,922 | 19,877 | 63,107 | 63,888 | 81,604 |
| b) Purchases of stock-in-trade | 9,417 | 13,914 | 5,963 | 31,252 | 18,885 | 34,225 |
| c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | 788 | 549 | 229 | 518 | 387 | (4,922) |
| d) Employee benefits expense (Refer note 3) | 16,354 | 16,046 | 14,166 | 48,067 | 42,227 | 56,538 |
| e) Finance costs | 185 | 202 | 1,152 | 819 | 3,220 | 4,052 |
| f) Depreciation and amortisation expenses | 4,118 | 4,085 | 3,337 | 12,204 | 9,552 | 13,524 |
| g) Other expenses | 20,234 | 20,327 | 18,306 | 60,518 | 55,120 | 74,477 |
| Total expenses | 71,114 | 73,045 | 63,030 | 2,16,485 | 1,93,279 | 2,59,498 |
| 5. Profit before tax (3-4) | 20,953 | 23,420 | 17,641 | 67,794 | 57,523 | 73,834 |
| 6. Tax expense | | | | | | |
| a) Current tax | 4,345 | 5,204 | 3,491 | 14,810 | 11,757 | 14,510 |
| b) Current tax - for earlier years | - | - | - | - | - | 39 |
| c) Deferred tax | 969 | 904 | 1,358 | 2,710 | 4,015 | 4,949 |
| Total tax expense | 5,314 | 6,108 | 4,849 | 17,520 | 15,772 | 19,498 |
| 7. Net profit after tax (5-6) | 15,639 | 17,312 | 12,792 | 50,274 | 41,751 | 54,336 |
| 8. Other comprehensive (loss)/income | | | | | | |
| a) (i) Items that will not be reclassified to profit or loss | (125) | (330) | (145) | (579) | (537) | (496) |
| (ii) Income tax on items that will not be reclassified to profit or loss | 32 | 83 | 36 | 146 | 135 | 125 |
| b) (i) Items that will be reclassified to profit or loss | (276) | (52) | 84 | (231) | (46) | (111) |
| (ii) Income tax on items that will be reclassified to profit or loss | 69 | 13 | (21) | 58 | 12 | 28 |
| Total other comprehensive (loss) (net of tax) | (300) | (286) | (46) | (606) | (436) | (454) |
| 9. Total comprehensive income after tax (7+8) | 15,339 | 17,026 | 12,746 | 49,668 | 41,315 | 53,882 |
| 10. Paid-up equity share capital (face value ₹ 1/- each) (Refer Note 5) | 1,555 | 1,553 | 1,550 | 1,555 | 1,550 | 1,552 |
| 11. Other equity | | | | | | 2,87,074 |
| 12. Earnings per share (face value ₹ 1/- each) (Refer Note 5) | | | | | | |
| a) Basic (₹) | *10.06 | *11.15 | *8.25 | *32.38 | *26.95 | 35.07 |
| b) Diluted (₹) | *9.87 | *10.92 | *8.11 | *31.74 | *26.50 | 34.30 |

*Not Annualised

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai - 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Energy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai - 400025, T:+91 22 24395200/5500

Notes:

1. The above standalone financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on February 04, 2025. The statutory auditors have carried out a limited review of the standalone financial results of the Company for the quarter and nine months ended December 31, 2024. The results of the Company are available for investors at www.jbpharma.com, www.nseindia.com and www.bseindia.com.
2. These standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
3. The employee benefits expense during the quarters ended on December 31, 2024, September 30, 2024, December 31, 2023, for the nine months ended December 31, 2024, December 31, 2023 and for the year ended March 31, 2024 includes charge of ₹ 1,544 lakhs, ₹ 1,368 lakhs, ₹ 1,141 lakhs, ₹ 3,996 lakhs, ₹ 2,890 lakhs and ₹ 4,014 lakhs respectively, towards equity-settled share-based payment transactions in terms of Ind AS 102 - 'Share-based Payment'.
4. The paid-up equity share capital of Company during the quarter ended on December 31, 2024 and for the nine months ended December 31, 2024 stands increased by ₹ 2.34 lakh and ₹ 3.54 lakhs upon allotment of 2,34,320 and 3,53,928 equity shares of ₹ 1 each pursuant to "ESOS Scheme".
5. During the nine months ended December 31, 2023, the Company on September 18, 2023 ("Record Date"), sub divided existing Equity shares of the Holding Company from 1 (One) Equity Share having face value of ₹ 2/- (Rupees Two only) each fully paid-up, into 2 (Two) Equity shares having face value of ₹ 1/- (Rupees One only) each fully paid up. Accordingly, earnings per share of comparative periods presented has been calculated based on number of shares outstanding in respective periods, as increased by sub-divided shares.
6. The Board of Directors, at its meeting held today, have declared an interim dividend of ₹ 8.5 per equity share of ₹ 1 each for the year 2024-25. The record date fixed for the purpose of ascertaining the entitlement is February 08, 2025.
7. The Company has only one reportable business segment viz. "Pharmaceuticals".

Mumbai
February 04, 2025

By order of the Board
For J.B. Chemicals & Pharmaceuticals Limited



Nikhil Chopra

Chief Executive Officer & Whole-time Director



Deloitte Haskins & Sells LLP

Chartered Accountants
One International Centre,
Tower 3, 31st Floor,
Senapati Bapat Marg,
Elphinstone Road (West),
Mumbai - 400 013,
Maharashtra, India

Phone: +91 22 6185 4000
Fax: +91 22 6185 4101

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF J. B. CHEMICALS & PHARMACEUTICALS LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **J. B. CHEMICALS & PHARMACEUTICALS LIMITED** ("the Company"), for the quarter and nine months ended December 31, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Rupen K. Bhatt
Partner

(Membership No.046930)

UDIN: 25046930BMODQD3389

Place: Mumbai

Date: February 04, 2025



GOOD PEOPLE
for **GOOD HEALTH**

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024

(₹ in lakhs)

| Particulars | Quarter ended | | | Nine months ended | | Year ended |
|--|---------------|------------|------------|-------------------|------------|------------|
| | 31-12-2024 | 30-09-2024 | 31-12-2023 | 31-12-2024 | 31-12-2023 | 31-03-2024 |
| | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| 1. Revenue from operations | 96,349 | 1,00,062 | 84,451 | 2,96,851 | 2,62,245 | 3,48,418 |
| 2. Other income | 800 | 995 | 735 | 2,384 | 2,064 | 3,727 |
| 3. Total income (1+2) | 97,149 | 1,01,057 | 85,186 | 2,99,235 | 2,64,309 | 3,52,145 |
| 4. Expenses | | | | | | |
| a) Cost of materials consumed | 20,023 | 17,920 | 19,894 | 63,106 | 63,910 | 81,628 |
| b) Purchases of stock-in-trade | 10,984 | 15,014 | 7,842 | 36,099 | 23,682 | 41,262 |
| c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | 667 | 908 | (373) | 286 | 585 | (4,685) |
| d) Employee benefits expense (Refer note 3) | 17,331 | 17,057 | 15,168 | 51,079 | 44,871 | 60,141 |
| e) Finance costs | 258 | 206 | 1,249 | 1,028 | 3,492 | 4,433 |
| f) Depreciation and amortisation expenses | 4,194 | 4,188 | 3,403 | 12,460 | 9,758 | 13,832 |
| g) Other expenses | 21,893 | 22,111 | 19,608 | 65,741 | 59,320 | 80,383 |
| Total expenses | 75,350 | 77,404 | 66,791 | 2,29,799 | 2,05,618 | 2,76,994 |
| 5. Profit before tax (3-4) | 21,799 | 23,653 | 18,395 | 69,436 | 58,691 | 75,151 |
| 6. Tax expense | | | | | | |
| a) Current tax | 4,611 | 5,385 | 3,624 | 15,443 | 12,154 | 15,062 |
| b) Current tax - for earlier years | - | - | - | - | - | 39 |
| c) Deferred tax | 939 | 811 | 1,414 | 2,604 | 3,890 | 4,787 |
| Total tax expense | 5,550 | 6,196 | 5,038 | 18,047 | 16,044 | 19,888 |
| 7. Net profit after tax (5-6) | 16,249 | 17,457 | 13,357 | 51,389 | 42,647 | 55,263 |
| 8. Other comprehensive (loss)/income | | | | | | |
| a) (i) Items that will not be reclassified to profit or loss | (125) | (330) | (145) | (579) | (537) | (496) |
| (ii) Income tax on items that will not be reclassified to profit or loss | 32 | 83 | 36 | 146 | 135 | 125 |
| b) (i) Items that will be reclassified to profit or loss | (1,459) | 499 | 243 | (130) | (637) | (1,146) |
| (ii) Income tax on items that will be reclassified to profit or loss | 61 | 22 | 6 | 58 | 2 | 55 |
| Total other comprehensive (loss)/income | (1,491) | 274 | 140 | (505) | (1,037) | (1,462) |
| 9. Total comprehensive income after tax (7+8) | 14,758 | 17,731 | 13,497 | 50,884 | 41,610 | 53,801 |
| 10. Net profit after tax for the period/year attributable to: | | | | | | |
| a) Owners of the company | 16,249 | 17,457 | 13,357 | 51,389 | 42,647 | 55,263 |
| b) Non-controlling interest | - | - | - | - | - | - |
| 11. Other comprehensive income for the period/year attributable to: | | | | | | |
| a) Owners of the company | (1,491) | 274 | 140 | (505) | (1,037) | (1,462) |
| b) Non-controlling interest | - | - | - | - | - | - |
| 12. Total comprehensive income attributable to : | | | | | | |
| a) Owners of the company | 14,758 | 17,731 | 13,497 | 50,884 | 41,610 | 53,801 |
| b) Non-controlling interest | - | - | - | - | - | - |
| 13. Paid-up equity share capital (face value ₹ 1/- each) (Refer Note 5) | 1,555 | 1,553 | 1,550 | 1,555 | 1,550 | 1,552 |
| 14. Other equity | | | | | | 2,90,781 |
| 15. Earnings per share (face value ₹ 1/- each) (Refer Note 5) | | | | | | |
| a) Basic (₹) | *10.46 | *11.24 | *8.62 | *33.09 | *27.53 | 35.66 |
| b) Diluted (₹) | *10.24 | *11.00 | *8.46 | *32.41 | *27.04 | 34.85 |

*Not Annualised

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T: +91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Energy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T: +91 22 24395200/5500

Notes:

1. The above consolidated financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on February 04, 2025. The statutory auditors have carried out a limited review of the consolidated financial results of the Company for the quarter and and nine months ended December 31, 2024. The results of the Company are available for investors at www.jbpharma.com, www.nseindia.com and www.bseindia.com.
2. These consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The consolidated financial results of the Holding Company, its wholly owned subsidiaries and step-down subsidiaries ("the Group") have been prepared by applying Ind AS 110 on Consolidated Financial Statements.
3. The employee benefits expense during the quarters ended on December 31, 2024, September 30, 2024, December 31, 2023, for the nine months ended December 31, 2024, December 31, 2023 and for the year ended March 31, 2024, includes charge of ₹ 1,580 lakhs, ₹ 1,399 lakhs, ₹ 1,186 lakhs, ₹ 4,103 lakhs, ₹ 3,028 lakhs and ₹ 4,197 lakhs respectively, towards equity-settled share-based payment transactions in terms of Ind AS 102 - 'Share-based Payment'.
4. The paid-up equity share capital of the Holding company during the quarter ended on December 31, 2024 and for the nine months ended December 31, 2024 stands increased by ₹ 2.34 lakh and ₹ 3.54 lakhs upon allotment of 2,34,320 and 3,53,928 equity shares of ₹ 1 each pursuant to "ESOS Scheme".
5. During the nine months ended December 31, 2023, the Holding Company on September 18, 2023 ("Record Date"), sub divided existing Equity shares of the Holding Company from 1 (One) Equity Share having face value of ₹ 2/- (Rupees Two only) each fully paid-up, into 2 (Two) Equity shares having face value of ₹ 1/- (Rupees One only) each fully paid up. Accordingly, earnings per share of comparative periods presented has been calculated based on number of shares outstanding in respective periods, as increased by sub-divided shares.
6. The Board of Directors, at its meeting held today, have declared an interim dividend of ₹ 8.5 per equity share of ₹ 1 each for the year 2024-25. The record date fixed for the purpose of ascertaining the entitlement is February 08, 2025.
7. The Group has only one reportable business segment viz., "Pharmaceuticals".

Mumbai
February 04, 2025

By order of the Board
For J.B. Chemicals & Pharmaceuticals Limited



Nikhil Chopra
Chief Executive Officer & Whole-time Director



Deloitte Haskins & Sells LLP

Chartered Accountants
One International Centre,
Tower 3, 31st Floor,
Senapati Bapat Marg,
Elphinstone Road (West),
Mumbai - 400 013,
Maharashtra, India

Phone: +91 22 6185 4000
Fax: +91 22 6185 4101

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF J. B. CHEMICALS & PHARMACEUTICALS LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **J. B. CHEMICALS & PHARMACEUTICALS LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and nine months ended December 31, 2024 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Parent - J. B. Chemicals & Pharmaceuticals Limited

Direct Subsidiaries - OOO Unique Pharmaceutical Laboratories; and
Unique Pharmaceutical Laboratories FZE.

Step down Subsidiaries - Biotech Laboratories (Pty.) Ltd.
JBCPL Philippines Inc.

Deloitte Haskins & Sells LLP

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of one subsidiary included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of Rs. 6,156.53 Lakhs and Rs. 18,908.45 Lakhs for the quarter and nine months ended December 31, 2024 respectively, total net profit after tax of Rs. 554.46 Lakhs and Rs. 1,493.89 Lakhs for the quarter and nine months ended December 31, 2024 respectively, total comprehensive income of Rs. 577.52 Lakhs and Rs. 1,493.89 Lakhs for the quarter and nine months ended December 31, 2024 respectively, as considered in the Statement. These interim financial information has been reviewed by another auditor whose report has been furnished to us and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

7. The consolidated unaudited financial results include the interim financial information of three subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total revenue of Rs. 2,986.69 Lakhs and Rs. 7,895.96 Lakhs for the quarter and nine months ended December 31, 2024 respectively, total net profit after tax of Rs. 239.31 Lakhs and Rs. 180.97 Lakhs for the quarter and nine months ended December 31, 2024 respectively, total comprehensive income of Rs. 239.31 Lakhs and Rs. 180.97 Lakhs for the quarter and nine months ended December 31, 2024 respectively, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Rupen K. Bhatt
Partner

(Membership No. 046930)

UDIN: 25046930BMOD0E8140

Place: Mumbai

Date: February 04, 2025

h.
@